News blog


  • BY: Andrew Hore |
  • POSTED: 07/06/2012 |

Sareum Holdings has raised £252,000 at 0.85p a share and this will be used to accelerate the company’s drug development programme.

The cancer drug discovery company had £530,000 in the bank at the end of 2011 as well as tax recoverable of £86,000. Sareum had raised £500,000 at 1p a share in February 2011.

In the six months to December 2011, the cash outflow from operations edged up from £332,000 to £349,000.

Sareum is making good progress with its research programmes. It has already decided on a pre-clinical development candidate for its Chk1 cancer programme. The research work for this programme is done by The Institute of Cancer Research. A dossier of information has been provided to potential licensing partners. The company believes that there is a strong appetite for licence deals and it expects a deal before the end of 2012.

At 0.9p a share, Sareum is valued at £13.1m.

Download the latest AIM Journal from

© 2024 Aim Micro. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Browse by issue
All issues
Popular tags
All tags

betbrokers, financial, gold, health, leisure, media, mobile, resources, services, technology

AIM Micro feeds

Keep up to date with articles published at Subscribe to AIM Micro RSS Feeds